Bonesupport Holding Third Quarter 2024 Earnings: EPS: kr0.47 (vs kr3.52 in 3Q 2023)

Simply Wall St

October 29, 2024

Bonesupport Holding (STO:BONEX) Third Quarter 2024 Results

Key Financial Results

Revenue: kr237.5m (up 50% from 3Q 2023).
Net income: kr30.6m (down 87% from 3Q 2023).
Profit margin: 13%.
EPS: kr0.47 (down from kr3.52 in 3Q 2023).

earnings-and-revenue-growth — OM:BONEX Earnings and Revenue Growth October 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bonesupport Holding Earnings Insights

Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 5.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Bonesupport Holding (of which 1 is significant!) you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Bonesupport Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.